UARK 2009-32 Compassionate Use Study of Carfilzomib

NO_LONGER_AVAILABLEEXPANDED_ACCESS
Timeline

Start Date

November 30, 2009

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Multiple Myeloma
Interventions
DRUG

Carfilzomib

"Carfilzomib (20mg/m2) IV push to be given at maximum rate of 10ml/minute on Days 1 and Day 2 of Cycle 1 only.~Carfilzomib (27mg/m2) IV bolus to be given at maximum rate of 10ml/minute on Day 8, 9, 15, and 16 of Cycle 1, then through Cycle 2 and beyond if initial dosing with 20mg/m2 tolerated.~For patients who tolerated 27mg/m2 through cycle 2 Days 1 and 2, Carfilzomib dose may be escalated to 36mg/m2 on days 8, 9, 15 and 16 of cycle 2. If tolerated, subsequent cycles will utilize 36mg/m2."

Trial Locations (1)

72205

University of Arkansas for Medical Sciences, Little Rock

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Onyx Therapeutics, Inc.

INDUSTRY

lead

University of Arkansas

OTHER